Showing 1,261 - 1,280 results of 75,155 for search '(( 5 ((we decrease) OR (mean decrease)) ) OR ( 50 ((n decrease) OR (a decrease)) ))', query time: 1.63s Refine Results
  1. 1261

    Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study by Jon Jarløv Rasmussen (2993427)

    Published 2016
    “…</p><p>Methods</p><p>This study had a cross-sectional case-control design and involved 37 current AAS abusers, 33 former AAS abusers (mean (95%CI) elapsed duration since AAS cessation: 2.5 (1.7; 3.7) years) and 30 healthy control participants. …”
  2. 1262
  3. 1263
  4. 1264

    Effect of busulfan treatment on vimentin, a supporting cytoskeletal protein. by Lingjun Zhao (21763122)

    Published 2025
    “…(<i>n</i> = 6 per group; Immunofluorescence staining; 400 × ; Scale bar = 50 μm).…”
  5. 1265
  6. 1266

    DataSheet_1_Accelerating Decreases in the Incidences of Hepatocellular Carcinoma at a Younger Age in Shanghai Are Associated With Hepatitis B Virus Vaccination.docx by Shunzhang Yu (12340927)

    Published 2022
    “…HCC incidences in males at younger age groups (age <50 years old), particularly in those with age <34 groups, showed an accelerating decrease over time, whereas HCC incidences significantly declined in the female population across all age groups except for those under 19 years of age. …”
  7. 1267

    DataSheet_1_Accelerating Decreases in the Incidences of Hepatocellular Carcinoma at a Younger Age in Shanghai Are Associated With Hepatitis B Virus Vaccination.docx by Shunzhang Yu (12340927)

    Published 2022
    “…HCC incidences in males at younger age groups (age <50 years old), particularly in those with age <34 groups, showed an accelerating decrease over time, whereas HCC incidences significantly declined in the female population across all age groups except for those under 19 years of age. …”
  8. 1268
  9. 1269

    Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”
  10. 1270

    Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  11. 1271

    Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    “…Outpatient visit frequency also significantly declined from 11.5 ± 4.3 visits in the year before surgery to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal-Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g004" target="_blank">Fig 4</a>).…”
  12. 1272

    Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  13. 1273
  14. 1274

    Pharmacologically induced torpor by 5′-AMP does not decrease platelet count despite decreased body temperature. by Edwin L. de Vrij (550179)

    Published 2014
    “…<p>A) Pharmacologically induced torpor by 5′-AMP in mice does not decrease platelet count during torpor and shows an increase upon arousal. …”
  15. 1275
  16. 1276
  17. 1277

    DAF-16/FOXO is Required for Locomotory Healthspan and Lifespan Benefits of Genetic Glycolysis Disruption. by Brian Onken (86790)

    Published 2020
    “…<i>daf-16</i> mutants are documented to have lowered locomotory ability vs. WT later in life [<a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1008982#pgen.1008982.ref091" target="_blank">91</a>, <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1008982#pgen.1008982.ref092" target="_blank">92</a>]; we note that, although comparison of scores across experiments is not possible due to variation in baseline values, the swimming rate of <i>daf-16(mgDf50)</i> control animals was slightly lower than WT controls on the same day of life (in <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1008982#pgen.1008982.g001" target="_blank">Fig 1C</a>; mean of 46.17 head thrashes/30 sec. for <i>daf-16</i> vs. 52.17 head thrashes/30 sec. for WT on day 10). …”
  18. 1278
  19. 1279
  20. 1280